Cardiorenal end points in a trial of aliskiren for type 2 diabetes

HH Parving, BM Brenner, JJV McMurray… - … England Journal of …, 2012 - Mass Medical Soc
Background This study was undertaken to determine whether use of the direct renin inhibitor
aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and …

[HTML][HTML] Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes

JJ Park - Diabetes & metabolism journal, 2021 - synapse.koreamed.org
The cardiovascular disease continuum begins with risk factors such as diabetes mellitus
(DM), progresses to vasculopathy and myocardial dysfunction, and finally ends with …

2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart …

CW Yancy, M Jessup, B Bozkurt, J Butler… - Journal of the American …, 2016 - jacc.org
The ACC, the AHA, and the Heart Failure Society of America (HFSA) recognize that the
introduction of effective new therapies that potentially affect a large number of patients …

Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses

M Brunström, B Carlberg - bmj, 2016 - bmj.com
Objective To assess the effect of antihypertensive treatment on mortality and cardiovascular
morbidity in people with diabetes mellitus, at different blood pressure levels. Design …

[HTML][HTML] Updated cardiovascular prevention guideline of the Brazilian Society of Cardiology-2019

DB Precoma, GMM Oliveira, AF Simao… - Arquivos brasileiros de …, 2019 - SciELO Brasil
Level of evidence Level A Data obtained from multiple concordant large randomized trials
and/or robust meta-analysis of randomized clinical trials Level B Data obtained from less …

Oxidative stress and heart failure

H Tsutsui, S Kinugawa… - American journal of …, 2011 - journals.physiology.org
Oxidative stress, defined as an excess production of reactive oxygen species (ROS) relative
to antioxidant defense, has been shown to play an important role in the pathophysiology of …

Gender differences in the effects of cardiovascular drugs

J Tamargo, G Rosano, T Walther… - European Heart …, 2017 - academic.oup.com
An initiation-promotion protocol was used to test the hypothesis that unleaded gasoline (UG)
vapor acts as a liver tumor promoter in female mice under exposure conditions in which UG …

Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and …

C Rosendorff, DT Lackland, M Allison, WS Aronow… - Circulation, 2015 - Am Heart Assoc
(AHA) scientific statement “Treatment of Hypertension in the Prevention and Management of
Ischemic Heart Disease: A Scientific Statement From the American Heart Association …

The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment

M Volpe, M Carnovali, V Mastromarino - Clinical Science, 2016 - portlandpress.com
After its discovery in the early 1980s, the natriuretic peptide (NP) system has been
extensively characterized and its potential influence in the development and progression of …

Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure

A Dei Cas, SS Khan, J Butler, RJ Mentz, RO Bonow… - JACC: Heart Failure, 2015 - jacc.org
The prevalence of patients with concomitant heart failure (HF) and diabetes mellitus (DM)
continues to increase with the general aging of the population. In patients with chronic HF …